Biodel Report issue

For profit Phase 1 Phase 3
Founded: Danbury CT United States (2003)
Status: Acquired by Albireo (2016) → now Ipsen (2023)

Organization Overview

First Clinical Trial
2006
NCT01000922
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (3)

insulin glargine (toujeo) (7 trials)

insulin human (humulin) (10 trials)

insulin lispro (humalog) (12 trials)

Drugs in Phase 1 Trials (1)

glucagon (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 3)

Hypoglycemia (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 4